Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) Return on equity
Johnson & Johnson's return on equity over the twelve months to 30 June 2026 was 25.7%, down 9.3 percentage points from fiscal 2025 (35.0%). Over the past ten years it has ranged from 0.00% (fiscal 2015) to 48.3% (fiscal 2023); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 6.97% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 35.0% | 14.97 |
| FY2024 | 20.1% | (28.23) |
| FY2023 | 48.3% | 24.50 |
| FY2022 | 23.8% | (6.62) |
| FY2021 | 30.4% | 6.44 |
| FY2020 | 24.0% | (1.39) |
| FY2019 | 25.4% | (0.15) |
| FY2018 | 25.5% | 23.52 |
| FY2017 | 1.99% | (21.61) |
| FY2016 | 23.6% | 23.60 |
Against its own ten years
Low 0.00%
High 48.3%
Ten-year median
24.0%
Current reading's percentile
91
Return on equity against peers
| Company | Return on equity |
|---|---|
| LLY Eli Lilly and Company compare | 102.3% |
| AMGN Amgen Inc. compare | 91.5% |
| NVS Novartis AG compare | 30.4% |
| JNJ Johnson & Johnson | 25.7% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. compare | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. compare | −208.1% |
| Drug Manufacturers General industry median | 6.97% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on JNJ
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement